Do risperidone or Lexapro (escitalopram) cause hypothyroidism?

Do Risperidone or Lexapro Cause Hypothyroidism?

Both risperidone and Lexapro (escitalopram) can cause hypothyroidism, though this is a rare adverse effect that is typically subclinical, asymptomatic, and reversible upon discontinuation.

Evidence for Lexapro (Escitalopram)

The FDA label for Lexapro does not list hypothyroidism as a recognized adverse effect 1. However, multiple case reports document escitalopram-induced hypothyroidism:

• Reversible subclinical hypothyroidism has been documented in patients taking escitalopram, occurring without significant clinical symptoms 2, 3
• A case of transient subclinical hypothyroidism developed in a 16-year-old male after escitalopram initiation, associated with acute suicidal ideation 4
• These cases consistently show reversibility when the medication is discontinued

Clinical Pattern with SSRIs

The mechanism appears related to SSRI effects on the hypothalamic-pituitary-thyroid axis. The hypothyroidism is typically:

• Subclinical (elevated TSH with normal T4)
• Asymptomatic
• Reversible upon drug discontinuation
• Develops after weeks to months of treatment

Evidence for Risperidone

The evidence for risperidone is more limited:

• A 2005 study found no significant changes in TSH levels with risperidone treatment over 6 weeks, though baseline thyroid abnormalities were common (13% had abnormal TSH) in schizophrenia patients 5
• A 2022 systematic review and observational study found that psychotropic medications as a class (including antipsychotics) were associated with biochemical isolated central hypothyroidism in 62% of referred patients 6
• The mechanism may involve suppression of TSH secretion via dopamine-serotonergic pathway antagonism 6

Important caveat: Quetiapine (another atypical antipsychotic) has stronger evidence for causing thyroid dysfunction, particularly decreased total T4 levels 5, 7. This suggests a class effect may exist for atypical antipsychotics, though risperidone-specific data is less robust.

Clinical Recommendations

Monitoring Strategy

• Baseline thyroid function (TSH, free T4) before initiating either medication, particularly in patients with:

  • Personal or family history of thyroid disease
  • Female sex (higher risk)
  • Advancing age
  • Pre-existing depression (independent thyroid dysfunction risk)

• Repeat thyroid function testing if:

  • New or worsening depressive symptoms develop during treatment
  • Clinical signs of hypothyroidism emerge (fatigue, weight gain, cold intolerance, cognitive slowing)
  • After 3-6 months of treatment in high-risk patients

Management if Hypothyroidism Develops

1. Confirm the diagnosis: Repeat TSH and free T4 after 6-12 weeks to distinguish transient from persistent changes 8
2. Consider drug discontinuation if clinically feasible, as the hypothyroidism is typically reversible
3. If TSH >10 mIU/L: Consider levothyroxine treatment while continuing the psychiatric medication if discontinuation is not possible 8
4. If TSH 4.5-10 mIU/L: Monitor every 6-12 months; treatment generally not indicated unless symptomatic 8

Key Pitfall to Avoid

Do not confuse symptoms of hypothyroidism with worsening depression or medication side effects. Both conditions share overlapping symptoms (fatigue, cognitive slowing, weight changes). Check thyroid function if psychiatric symptoms worsen unexpectedly during treatment, as untreated hypothyroidism can worsen the underlying psychiatric condition and may even precipitate psychosis ("myxedema madness") 9.

The risk is low but real, and routine screening in all patients is not necessary based on current evidence. However, maintain clinical vigilance, particularly in the first 6 months of treatment.